237 related articles for article (PubMed ID: 38382459)
1. Emerging potential of immunopeptidomics by mass spectrometry in cancer immunotherapy.
Minegishi Y; Haga Y; Ueda K
Cancer Sci; 2024 Apr; 115(4):1048-1059. PubMed ID: 38382459
[TBL] [Abstract][Full Text] [Related]
2. Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment.
Newey A; Griffiths B; Michaux J; Pak HS; Stevenson BJ; Woolston A; Semiannikova M; Spain G; Barber LJ; Matthews N; Rao S; Watkins D; Chau I; Coukos G; Racle J; Gfeller D; Starling N; Cunningham D; Bassani-Sternberg M; Gerlinger M
J Immunother Cancer; 2019 Nov; 7(1):309. PubMed ID: 31735170
[TBL] [Abstract][Full Text] [Related]
3. 'Hotspots' of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization.
Müller M; Gfeller D; Coukos G; Bassani-Sternberg M
Front Immunol; 2017; 8():1367. PubMed ID: 29104575
[TBL] [Abstract][Full Text] [Related]
4. Proteogenomic analysis identifies neoantigens and bacterial peptides as immunotherapy targets in colorectal cancer.
Yao P; Gao M; Hu W; Wang J; Wang Y; Wang Q; Ji J
Pharmacol Res; 2024 Jun; 204():107209. PubMed ID: 38740147
[TBL] [Abstract][Full Text] [Related]
5. Differential ion mobility mass spectrometry in immunopeptidomics identifies neoantigens carrying colorectal cancer driver mutations.
Minegishi Y; Kiyotani K; Nemoto K; Inoue Y; Haga Y; Fujii R; Saichi N; Nagayama S; Ueda K
Commun Biol; 2022 Aug; 5(1):831. PubMed ID: 35982173
[TBL] [Abstract][Full Text] [Related]
6. The Importance of Being Presented: Target Validation by Immunopeptidomics for Epitope-Specific Immunotherapies.
Becker JP; Riemer AB
Front Immunol; 2022; 13():883989. PubMed ID: 35464395
[TBL] [Abstract][Full Text] [Related]
7. Unlocking the potential of microfluidics in mass spectrometry-based immunopeptidomics for tumor antigen discovery.
Stutzmann C; Peng J; Wu Z; Savoie C; Sirois I; Thibault P; Wheeler AR; Caron E
Cell Rep Methods; 2023 Jun; 3(6):100511. PubMed ID: 37426761
[TBL] [Abstract][Full Text] [Related]
8. Antigen discovery for the development of cancer immunotherapy.
Ahn R; Cui Y; White FM
Semin Immunol; 2023 Mar; 66():101733. PubMed ID: 36841147
[TBL] [Abstract][Full Text] [Related]
9. TOF
Hoenisch Gravel N; Nelde A; Bauer J; Mühlenbruch L; Schroeder SM; Neidert MC; Scheid J; Lemke S; Dubbelaar ML; Wacker M; Dengler A; Klein R; Mauz PS; Löwenheim H; Hauri-Hohl M; Martin R; Hennenlotter J; Stenzl A; Heitmann JS; Salih HR; Rammensee HG; Walz JS
Nat Commun; 2023 Nov; 14(1):7472. PubMed ID: 37978195
[TBL] [Abstract][Full Text] [Related]
10. Application of mass spectrometry-based MHC immunopeptidome profiling in neoantigen identification for tumor immunotherapy.
Zhang X; Qi Y; Zhang Q; Liu W
Biomed Pharmacother; 2019 Dec; 120():109542. PubMed ID: 31629254
[TBL] [Abstract][Full Text] [Related]
11. Sensitive Immunopeptidomics by Leveraging Available Large-Scale Multi-HLA Spectral Libraries, Data-Independent Acquisition, and MS/MS Prediction.
Pak H; Michaux J; Huber F; Chong C; Stevenson BJ; Müller M; Coukos G; Bassani-Sternberg M
Mol Cell Proteomics; 2021; 20():100080. PubMed ID: 33845167
[TBL] [Abstract][Full Text] [Related]
12. Challenges and opportunities in analyzing and modeling peptide presentation by HLA-II proteins.
ElAbd H; Bacher P; Tholey A; Lenz TL; Franke A
Front Immunol; 2023; 14():1107266. PubMed ID: 37063883
[TBL] [Abstract][Full Text] [Related]
13. Precision Neoantigen Discovery Using Large-Scale Immunopeptidomes and Composite Modeling of MHC Peptide Presentation.
Pyke RM; Mellacheruvu D; Dea S; Abbott C; Zhang SV; Phillips NA; Harris J; Bartha G; Desai S; McClory R; West J; Snyder MP; Chen R; Boyle SM
Mol Cell Proteomics; 2023 Apr; 22(4):100506. PubMed ID: 36796642
[TBL] [Abstract][Full Text] [Related]
14. Neoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy?
Roerden M; Nelde A; Walz JS
Front Immunol; 2019; 10():3004. PubMed ID: 31921218
[TBL] [Abstract][Full Text] [Related]
15. Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry.
Freudenmann LK; Marcu A; Stevanović S
Immunology; 2018 Jul; 154(3):331-345. PubMed ID: 29658117
[TBL] [Abstract][Full Text] [Related]
16. The Human Immunopeptidome Project: A Roadmap to Predict and Treat Immune Diseases.
Vizcaíno JA; Kubiniok P; Kovalchik KA; Ma Q; Duquette JD; Mongrain I; Deutsch EW; Peters B; Sette A; Sirois I; Caron E
Mol Cell Proteomics; 2020 Jan; 19(1):31-49. PubMed ID: 31744855
[TBL] [Abstract][Full Text] [Related]
17. Discrimination Between Human Leukocyte Antigen Class I-Bound and Co-Purified HIV-Derived Peptides in Immunopeptidomics Workflows.
Partridge T; Nicastri A; Kliszczak AE; Yindom LM; Kessler BM; Ternette N; Borrow P
Front Immunol; 2018; 9():912. PubMed ID: 29780384
[TBL] [Abstract][Full Text] [Related]
18. IMBAS-MS Discovers Organ-Specific HLA Peptide Patterns in Plasma.
Wahle M; Thielert M; Zwiebel M; Skowronek P; Zeng WF; Mann M
Mol Cell Proteomics; 2024 Jan; 23(1):100689. PubMed ID: 38043703
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in immunopeptidomic-based tumor neoantigen discovery.
Meng W; Schreiber RD; Lichti CF
Adv Immunol; 2023; 160():1-36. PubMed ID: 38042584
[TBL] [Abstract][Full Text] [Related]
20. Mass Spectrometry Based Immunopeptidomics for the Discovery of Cancer Neoantigens.
Bassani-Sternberg M
Methods Mol Biol; 2018; 1719():209-221. PubMed ID: 29476514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
